Literature DB >> 27356193

Psoriasis and psoriatic arthritis overview.

Alan Menter1.   

Abstract

Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases that primarily affect the skin and joints, respectively; these diseases are also associated with high rates of cardiovascular and other comorbidities. Despite over 40 genes proven to be related to the disease, the exact causes of psoriasis and PsA are still to be determined. Recent insights into the underlying pathophysiology of these diseases have revealed novel therapeutic targets. Effective management requires timely diagnosis and initiation of treatment. Yet, both psoriasis and PsA remain underrecognized and undertreated in current clinical practice. Recognizing the true physical, social, and emotional burden of psoriasis and PsA, as well as their associated comorbidities, is the first step to improving the prognosis for affected patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27356193

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  19 in total

1.  Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.

Authors:  Antonio Costanzo; Filomena Russo; Marco Galluzzo; Luca Stingeni; Roberta Scuderi; Leonardo Zichichi; Manuela Papini; Luisa Di Costanzo; Andrea Conti; Martina Burlando; Andrea Chiricozzi; Francesca Maria Gaiani; Cristina Mugheddu; Maria Letizia Musumeci; Paolo Gisondi; Stefano Piaserico; Paolo Dapavo; Marina Venturini; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Ketty Peris; Franca Cantoresi; Sara Trevisini; Francesco Loconsole; Annamaria Offidani; Santo Raffaele Mercuri; Viviana Lora; Francesca Prignano; Marta Bartezaghi; Giovanni Oliva; Elisabetta Aloisi; Roberto Orsenigo
Journal:  Acta Derm Venereol       Date:  2021-10-21       Impact factor: 3.875

2.  Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.

Authors:  Marina Talamonti; Giovanna Malara; Ylenia Natalini; Federico Bardazzi; Andrea Conti; Andrea Chiricozzi; Cristina Mugheddu; Paolo Gisondi; Stefano Piaserico; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Franca Cantoresi; Maria Concetta Fargnoli; Anna Balato; Francesco Loconsole; Annamaria Offidani; Claudio Bonifati; Francesca Prignano; Marta Bartezaghi; Alice Rausa; Elisabetta Aloisi; Roberto Orsenigo; Antonio Costanzo
Journal:  Acta Derm Venereol       Date:  2021-03-31       Impact factor: 3.875

3.  Prokineticin 2 Plays a Pivotal Role in Psoriasis.

Authors:  Xiaoqin He; Chuanbin Shen; Qiumin Lu; Jiong Li; Yuquan Wei; Li He; Ruizhen Bai; Jie Zheng; Ning Luan; Zhiye Zhang; Mingqiang Rong; Ren Lai
Journal:  EBioMedicine       Date:  2016-10-19       Impact factor: 8.143

4.  Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.

Authors:  Mamitaro Ohtsuki; Akimichi Morita; Atsuyuki Igarashi; Shinichi Imafuku; Yayoi Tada; Hiroyuki Fujita; Ayako Fujishige; Masako Yamaguchi; Rie Teshima; Yumiko Tani; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2017-05-23       Impact factor: 4.005

5.  Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors.

Authors:  Andreas Pinter; Georgios Kokolakis; Juergen Rech; Mona H C Biermann; Benjamin M Häberle; Jan Multmeier; Maximilian Reinhardt
Journal:  Dermatol Ther (Heidelb)       Date:  2020-06-04

6.  Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination.

Authors:  Vibeke Strand; Philip J Mease; Ervant J Maksabedian Hernandez; Bradley S Stolshek; Lyrica X H Liu; David H Collier; Gregory Kricorian; Joseph F Merola
Journal:  RMD Open       Date:  2021-01

7.  Genetic diagnosis history and osteoarticular phenotype of a non-transfusion secondary hemochromatosis.

Authors:  Dan-Dan Ruan; Yu-Mian Gan; Tao Lu; Xiao Yang; Yao-Bin Zhu; Qing-Hua Yu; Li-Sheng Liao; Ning Lin; Xin Qian; Jie-Wei Luo; Fa-Qiang Tang
Journal:  World J Clin Cases       Date:  2020-12-06       Impact factor: 1.337

8.  Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi-case report analysis.

Authors:  Carmen Fiorella
Journal:  Clin Case Rep       Date:  2022-01-28

9.  Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis.

Authors:  Carina Borst; Farideh Alasti; Josef S Smolen; Daniel Aletaha
Journal:  RMD Open       Date:  2021-12

Review 10.  Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis.

Authors:  Angelo Fassio; Peter Matzneller; Luca Idolazzi
Journal:  Front Med (Lausanne)       Date:  2020-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.